News Related to Caplyta

Related coverage linked through entity extraction aliases.

Johnson & Johnson Reports Strong Q4 2025 Results, Faces Ongoing Talc Litigation Challenges

Mar 29, 2026

Johnson & Johnson reported strong Q4 2025 earnings with $2.46 adjusted EPS and $24.56 billion in sales, beating estimates. The company faces over 67,000 active talc lawsuits following recent trial losses while projecting 2026 sales of $100-101 billion and maintaining a robust pipeline with recent FDA approvals and breakthrough designations.

FDA Approves Vanda's Bysanti for Schizophrenia and Bipolar I Disorder

Feb 21, 2026

The U.S. Food and Drug Administration has approved Vanda Pharmaceuticals' Bysanti for treating schizophrenia and acute bipolar I disorder. The company expects to launch the drug in the third quarter of 2026.